featured
Lenalidomide vs Placebo Maintenance After Single ASCT for Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Updated Analysis of CALGB (Alliance) 100104 Assessing Lenalidomide Versus Placebo Maintenance After Single Autologous Stem-Cell Transplantation for Multiple Myeloma: A Randomised, Double-Blind, Phase 3 Trial
Lancet Haematol 2017 Aug 17;[EPub Ahead of Print], SA Holstein, SH Jung, PG Richardson, CC Hofmeister, DD Hurd, H Hassoun, S Giralt, EA Stadtmauer, DJ Weisdorf, R Vij, JS Moreb, NS Callander, K van Besien, TG Gentile, L Isola, RT Maziarz, A Bashey, H Landau, T Martin, MH Qazilbash, C Rodriguez, B McClune, RL Schlossman, SE Smith, V Hars, K Owzar, C Jiang, M Boyd, C Schultz, M Wilson, P Hari, MC Pasquini, MM Horowitz, TC Shea, SM Devine, C Linker, KC Anderson, PL McCarthyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.